Thrombosis and Haemostasis 2020 Editors' Choice Papers

In this Editor's choice, we highlight last year's papers from Thrombosis and Haemostasis as well as from its open access companion journal THOpen, which found most resonance among our readers' community, holding promise for mechanistic understanding and improved clinical management in the fields of Thrombosis and Haemostasis. Building on the research investigations from this undoubtedly memorable year may be particularly useful to overcome the current pandemic situation. As it became apparent that coronavirus disease 2019 (COVID-19) was not merely a pulmonary disease but that thrombosis was a key element involved in its severity and complications, the thrombosis research community deployed intensive research efforts in the hope to optimize treatment and/or prophylaxis as well as to decipher the mechanisms and characteristics of COVID-19 thrombosis as rapidly as possible. Due to the urgency of the pandemic development, it was indeed not surprising that publications relating to COVID-19 received by far the most attention in 2020.

Publikationsverlauf

Eingereicht: 01. Dezember 2020

Angenommen: 01. Dezember 2020

Artikel online veröffentlicht:
21. Januar 2021

• References

• 1 Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb Haemost 2020; 120 (05) 876-878
• 2 Spiezia L, Boscolo A, Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120 (06) 998-1000
• 3 Jin S, Jin Y, Xu B, Hong J, Yang X. Prevalence and impact of coagulation dysfunction in COVID-19 in China: a meta-analysis. Thromb Haemost 2020; 120 (11) 1524-1535
• 4 Boscolo A, Spiezia L, Correale C. et al. Different hypercoagulable profiles in patients with COVID-19 admitted to the internal medicine ward and the intensive care unit. Thromb Haemost 2020; 120 (10) 1474-1477
• 5 Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb Haemost 2020; 120 (06) 949-956
• 6 Marchandot B, Trimaille A, Curtiaud A. et al. Staging severity of COVID-19 according to hemostatic abnormalities (CAHA score). Thromb Haemost 2020; 120 (12) 1716-1719
• 7 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
• 8 Zhai Z, Li C, Chen Y. et al; Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 2020; 120 (06) 937-948
• 9 Grandmaison G, Andrey A, Périard D. et al. Systematic screening for venous thromboembolic events in COVID-19 pneumonia. TH Open 2020; 4 (02) e113-e115
• 10 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
• 11 Cattaneo M, Bertinato EM, Birocchi S. et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified?. Thromb Haemost 2020; 120 (08) 1230-1232
• 12 Morici N, Bottiroli M, Fumagalli R, Marini C, Cattaneo M. Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink. Thromb Haemost 2020; 120 (09) 1339-1342
• 13 Eriksson O, Hultström M, Persson B. et al. Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients. Thromb Haemost 2020; 120 (12) 1720-1724
• 14 Vaughan CJ, Cronin H, Ryan PM, Caplice NM. Obesity and COVID-19: a Virchow's triad for the 21st century. Thromb Haemost 2020; 120 (11) 1590-1593
• 15 Miesbach W. Pathological role of angiotensin II in severe COVID-19. TH Open 2020; 4 (02) e138-e144
• 16 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020
• 17 Potpara TS, Lip GYH, Blomstrom-Lundqvist C. et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb Haemost 2020; DOI: 10.1055/s-0040-1716408.
• 18 Yoon M, Yang PS, Jang E. et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb Haemost 2019; 119 (10) 1695-1703
• 19 Nielsen PB, Overvad TF. Female sex as a risk modifier for stroke risk in atrial fibrillation: using CHA2DS2-VASc versus CHA2DS2-VA for stroke risk stratification in atrial fibrillation: a note of caution. Thromb Haemost 2020; 120 (06) 894-898
• 20 Chao TF, Liao JN, Tuan TC. et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients. Thromb Haemost 2019; 119 (07) 1162-1170
• 21 Pandey AK, Xu K, Zhang L. et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 2020; 120 (03) 484-494
• 22 Chao T-F, Guo Y. Should we adopt a standard international normalized ratio range of 2.0 to 3.0 for Asian patients with atrial fibrillation? An appeal for evidence-based management, not eminence-based recommendations. Thromb Haemost 2020; 120 (03) 366-368
• 23 Kim HK, Tantry US, Smith SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2020; DOI: 10.1055/s-0040-1718729.
• 24 Martin AC, Thomas W, Mahir Z. et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study. Thromb Haemost 2020
• 25 Boriani G, Ruff CT, Kuder JF. et al. Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial. Thromb Haemost 2020
• 26 Spyropoulos AC, Lipardi C, Xu J. et al. Modified IMPROVE VTE risk score and elevated D-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open 2020; 4 (01) e59-e65
• 27 Harenberg J, Beyer-Westendorf J, Crowther M. et al; Working Group Members. Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine-a multicenter trial. Thromb Haemost 2020; 120 (01) 132-140
• 28 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-stroke and ABC-bleeding scores in patients with atrial fibrillation: the Murcia AF project. Thromb Haemost 2020; 120 (08) 1200-1207
• 29 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
• 30 Radin M, Foddai SG, Cecchi I. et al. Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 2020; 120 (04) 592-598
• 31 Pieters M, Guthold M, Nunes C. et al. Interpretation and validation of maximum absorbance data obtained from turbidimetry analysis of plasma clots. Thromb Haemost 2020; 120 (01) 44-54
• 32 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2019 Editor's Choice Papers. Thromb Haemost 2020; 120 (01) 184-190
• 33 Franchi F, Rollini F, Garcia E. et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT study. Thromb Haemost 2020; 120 (01) 83-93
• 34 Gorog DA, Geisler T. Platelet inhibition in acute coronary syndrome and percutaneous coronary intervention: insights from the past and present. Thromb Haemost 2020; 120 (04) 565-578
• 35 Weitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost 2020; 120 (08) 1147-1158
• 36 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
• 37 Cavallari I, Verolino G, Romano S, Patti G. Efficacy and safety of nonvitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
• 38 Abrahami D, Renoux C, Yin H, Fournier JP, Azoulay L. The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation. Thromb Haemost 2020; 120 (10) 1384-1394
• 39 Weitz JI, Raskob GE, Spyropoulos AC. et al. Thromboprophylaxis with rivaroxaban in acutely ill medical patients with renal impairment: insights from the MAGELLAN and MARINER trials. Thromb Haemost 2020; 120 (03) 515-524
• 40 Hwang J, Han S, Bae H-J. et al. NOAC adherence of patients with atrial fibrillation in the real world: dosing frequency matters?. Thromb Haemost 2020; 120 (02) 306-313
• 41 Proietti M, Lane DA. The compelling issue of nonvitamin K antagonist oral anticoagulant adherence in atrial fibrillation patients: a systematic need for new strategies. Thromb Haemost 2020; 120 (03) 369-371
• 42 Ivany E, Lane DA. Patient satisfaction: a key component in increasing treatment adherence and persistence. Thromb Haemost 2020; DOI: 10.1055/s-0040-1718734.
• 43 Ding WY, Mandrola J, Gupta D. Left atrial appendage occlusion: past, present and future. Thromb Haemost 2020; 120 (11) 1484-1491
• 44 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
• 45 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019; 119 (09) 1384-1393
• 46 Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost 2020; 120 (10) 1357-1370
• 47 Cortesi PA, Castaman G, Trifirò G. et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120 (02) 216-228
• 48 Pastori D, Farcomeni A, Milanese A. et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (05) 866-875
• 49 d'Alessandro E, Becker C, Bergmeier W. et al; Scientific Reviewer Committee. Thrombo-inflammation in cardiovascular disease: an expert consensus document from the Third Maastricht Consensus Conference on Thrombosis. Thromb Haemost 2020; 120 (04) 538-564
• 50 van der Vorst EPC, Daissormont I, Aslani M. et al. Interruption of the CXCL13/CXCR5 chemokine axis enhances plasma IgM levels and attenuates atherosclerosis development. Thromb Haemost 2020; 120 (02) 344-347
• 51 Hoffmann J, Fišer K, Liebetrau C. et al. High-content immunophenotyping and hierarchical clustering reveal sources of heterogeneity and new surface markers of human blood monocyte subsets. Thromb Haemost 2020; 120 (01) 141-155
• 52 Kimball AS, Obi AT, Luke CE. et al. Ly6CLo monocyte/macrophages are essential for thrombus resolution in a murine model of venous thrombosis. Thromb Haemost 2020; 120 (02) 289-299
• 53 Knopp T, Karbach S, Wenzel P. Myeloid cells to the rescue: improving thrombus resolution. Thromb Haemost 2020; 120 (02) 197-198
• 54 Stakos D, Skendros P, Konstantinides S, Ritis K. Traps N′ clots: NET-mediated thrombosis and related diseases. Thromb Haemost 2020; 120 (03) 373-383
• 55 Gavriilaki E, Touloumenidou T, Sakellari I. et al. Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy. Thromb Haemost 2020; 120 (04) 638-646
• 56 Tilburg J, Michaud SA, Maracle CX. et al. Plasma protein signatures of a murine venous thrombosis model and Slc44a2 knockout mice using quantitative-targeted proteomics. Thromb Haemost 2020; 120 (03) 423-436
• 57 Scheller I, Nieswandt B. Novel approaches to unravel risk factors and mechanisms of venous thrombosis. Thromb Haemost 2020; 120 (03) 372
• 58 Roka-Moiia Y, Walk R, Palomares DE. et al. Platelet activation via shear stress exposure induces a differing pattern of biomarkers of activation versus biochemical agonists. Thromb Haemost 2020; 120 (05) 776-792
• 59 Zhou L, Gao N, Sun H. et al. Effects of native fucosylated glycosaminoglycan, its depolymerized derivatives on intrinsic factor Xase, coagulation, thrombosis, and hemorrhagic risk. Thromb Haemost 2020; 120 (04) 607-619